Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Romiplostim in ITP
NCT00117143Phase 2Completed
- Sponsor
- Amgen
- Start
- Dec 2002
- Primary completion
- Jul 2004
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in immune thrombocytopenic purpura (ITP), sponsored by Amgen. Primary endpoints: Number of Participants With Adverse Events at 11 weeks and Number of Participants With Positive Anti-Romiplostim Antibodies at Day 78. Started Dec 2002; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00117143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117143.